SPECC1 and COVID-19: Targets, such as NSP3, NSP5 and NSP12, have highly conserved binding sites, which make them attractive drug targets, and there has been minimal research into how trialled drugs will affect both mild and severe CoVs, but COVID-19 always remained the prime focus [168].